Table 1.
Baseline Characteristics of Analyzed Patients (n = 263)
| Characteristics | Total (n = 263) | max BTS > 50 mm (n = 128) | max BTS ≤ 50 mm (n = 135) | p |
|---|---|---|---|---|
| Age, median (range), years | ||||
| Median (range), years | 69 (31–88) | 67 (37–87) | 71 (31–88) | 0.004 |
| Age group, n | ||||
| < 75 years | 189 (71.9) | 99 (77.3) | 90 (66.7) | 0.057 |
| ≥ 75 years | 74 (28.1) | 29 (22.7) | 45 (33.3) | |
| Sex, n (%) | ||||
| Female | 82 (31.2) | 41 (32.0) | 41 (30.4) | 0.791 |
| Smoking status | ||||
| Brinkman index ≥ 400 | 199 (75.7) | 90 (70.3) | 109 (80.7) | 0.061 |
| ECOG-PS, n (%) | ||||
| 0/1 | 183 (69.6) | 74 (57.8) | 109 (80.7) | < 0.001 |
| ≥ 2 | 80 (30.4) | 54 (42.2) | 26 (19.3) | |
| Histological subtypes, n (%) | ||||
| Adenocarcinoma | 165 (62.7) | 74 (57.8) | 91 (67.4) | 0.269 |
| Squamous cell carcinoma | 64 (24.3) | 34 (26.6) | 30 (22.2) | |
| NSCLC, NOS | 25 (9.5) | 16 (12.5) | 9 (6.7) | |
| Other | 9 (3.4) | 4 (3.1) | 5 (3.7) | |
| Staging, n (%) | ||||
| III | 16 (6.1) | 6 (4.7) | 10 (7.4) | 0.001 |
| IVA | 50 (19.0) | 32 (25.0) | 18 (13.3) | |
| IVB | 115 (43.7) | 64 (50.0) | 51 (37.8) | |
| Recurrence | 82 (31.2) | 26 (20.3) | 56 (41.5) | |
| Number of organs involved | ||||
| 0 or 1 | 101 (38.4) | 40 (31.2) | 61 (45.2) | 0.023 |
| ≥ 2 | 162 (61.6) | 88 (68.8) | 74 (54.8) | |
| Presence of brain metastasis, n (%) | ||||
| Yes | 66 (25.1) | 38 (29.7) | 28 (20.7) | 0.117 |
| Presence of bone metastasis, n (%) | ||||
| Yes | 86 (32.7) | 56 (43.8) | 30 (22.2) | < 0.001 |
| Presence of liver metastasis, n (%) | ||||
| Yes | 52 (19.8) | 32 (25.0) | 20 (14.8) | 0.044 |
| PD-L1 expression, n (%) | ||||
| < 1% | 43 (16.3) | 23 (18.0) | 20 (14.8) | 0.92 |
| 1–49% | 39 (14.8) | 18 (14.1) | 21 (15.6) | |
| ≥ 50% | 79 (30.0) | 38 (29.7) | 41 (30.4) | |
| Unknown | 102 (38.8) | 49 (38.3) | 53 (39.3) | |
| EGFR mutation status, n (%) | ||||
| Positive | 27 (10.3) | 15 (11.7) | 12 (8.9) | 0.659 |
| Negative | 205 (77.9) | 97 (75.8) | 108 (80.0) | |
| Unknown | 31 (11.8) | 16 (12.5) | 15 (11.1) | |
| Initially chosen ICI, n (%) | ||||
| Atezolizumab | 43 (16.3) | 21 (16.4) | 22 (16.3) | 0.971 |
| Nivolumab | 140 (53.2) | 67 (52.3) | 73 (54.1) | |
| Pembrolizumab | 80 (30.4) | 40 (31.2) | 40 (29.6) | |
| Lines of previous chemotherapy, n (%) | ||||
| 0 | 58 (22.1) | 32 (25.0) | 26 (19.3) | 0.192 |
| 1 | 122 (46.4) | 52 (40.6) | 70 (51.9) | |
| ≥ 2 | 83 (31.5) | 44 (34.4) | 39 (28.9) | |
| Albumin, g/dL | ||||
| Median (IQR) | 3.6 (3.0–4.0) | 3.3 (2.7–3.7) | 3.9 (3.4–4.2) | < 0.001 |
| LDH, U/L | ||||
| Median (IQR) | 214.5 (182.0–292.0) | 239.0 (188.0–374.5) | 202.5 (175.3–244.0) | < 0.001 |
| NLR | ||||
| Median (IQR) | 4.1 (2.5–6.3) | 5.0 (3.2–8.4) | 3.1 (2.1–5.0) | < 0.001 |
| GRIm score, n (%) | ||||
| 0 | 92 (36.4) | 19 (15.3) | 73 (56.6) | < 0.001 |
| 1 | 74 (29.2) | 40 (32.3) | 34 (26.4) | |
| 2 | 64 (25.3) | 47 (37.9) | 17 (13.2) | |
| 3 | 23 (9.1) | 18 (14.5) | 5 (3.9) | |
BTS baseline tumor size, ECOG-PS Eastern Cooperative Oncology Group-performance status, NSCLC non-small-cell lung cancer; NOS not otherwise specified, PD-L1 programmed death-ligand 1, EGFR epidermal growth factor receptor, ICI immune checkpoint inhibitor, IQR interquartile range, LDH lactate dehydrogenase, NLR neutrophil to lymphocyte ratio, GRIm score Gustave Roussy Immune Score